According to this evidence, ADA states that in patients with T2D and established CVD, multiple CVD risk factors, or diabetic kidney disease, an SGLT-2 inhibitor with demonstrated cardiovascular benefit is recommended to reduce the risk of MACE and/or hospitalization for HF [9]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.